Skip to main content
Erschienen in: High Blood Pressure & Cardiovascular Prevention 3/2023

18.05.2023 | Original article

Blood Pressure Association with the 8-Item Morisky Medication Adherence Scale in Hypertensive Adults from Low-Resource Primary Care Settings: Results from a Prospective Cohort Nested within a Randomised Controlled Trial

verfasst von: Pablo Elías Gulayin, Andrea Beratarrechea, Rosana Poggio, Luz Gibbons, Analía Nejamis, Marilina Santero, Adolfo Rubinstein, Vilma Irazola

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

One of the self-report adherence scales most widely used is the 8-item Morisky Medication Adherence Scale (MMAS-8).

Aim

To evaluate construct validity and reliability of the MMAS-8 in hypertensive adults from low-resource settings within the public primary care level in Argentina.

Methods

Prospective data from hypertensive adults under antihypertensive pharmacological treatment that participated in the “Hypertension Control Program in Argentina” study was analyzed. Participants were followed at baseline, 6, 12 and 18 months. Based on MMAS-8, adherence was defined as low (score < 6), medium (score 6 to < 8) and high (score of 8).

Results

1214 participants were included in the analysis. In comparison to low adherence, high adherence category was associated with a reduction of − 5.6 mmHg (CI 95%: − 7.2; − 4.0) in systolic blood pressure (BP) and − 3.2 mmHg (CI 95%: − 4.2; − 2.2) in diastolic BP; and with a 56% higher likelihood to have controlled BP (p < .0001). Among those participants with baseline score ≤ 6, two points increase in MMAS-8 along follow-up showed a tendency to reduce BP in almost all-time points and a 34% higher likelihood of having controlled BP at the end of the follow-up (p = 0.0039). Cronbach’s alpha total-item values in all time-points were higher than 0.70.

Conclusions

Higher MMAS-8 categories were positively associated with BP reduction and higher likelihood of BP control over time. Internal consistency was acceptable and in line with previous studies.
Literatur
1.
Zurück zum Zitat Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Curr Hypertens Rep. 2013;15(3):134–6.CrossRefPubMedPubMedCentral Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Curr Hypertens Rep. 2013;15(3):134–6.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50.CrossRefPubMedPubMedCentral Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Ismail NH, Puoane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S, Investigators PS. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959–68.CrossRefPubMed Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Ismail NH, Puoane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S, Investigators PS. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959–68.CrossRefPubMed
5.
Zurück zum Zitat Irazola VE, Gutierrez L, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gaziano T, Levitt NS, Miranda JJ, Ortiz AB, Steyn K, Wu Y, Xavier D, Yan LL, He J, Rubinstein A. Hypertension prevalence, awareness, treatment, and control in selected LMIC communities: results from the NHLBI/UHG network of centers of excellence for chronic diseases. Glob Heart. 2016;11(1):47–59.CrossRefPubMed Irazola VE, Gutierrez L, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gaziano T, Levitt NS, Miranda JJ, Ortiz AB, Steyn K, Wu Y, Xavier D, Yan LL, He J, Rubinstein A. Hypertension prevalence, awareness, treatment, and control in selected LMIC communities: results from the NHLBI/UHG network of centers of excellence for chronic diseases. Glob Heart. 2016;11(1):47–59.CrossRefPubMed
7.
Zurück zum Zitat Lindenfeld J, Jessup M. “Drugs don’t work in patients who don’t take them” (C. Everett Koop, MD, US Surgeon General, 1985). Eur J Heart Fail. 2017;19(11):1412–3.CrossRefPubMed Lindenfeld J, Jessup M. “Drugs don’t work in patients who don’t take them” (C. Everett Koop, MD, US Surgeon General, 1985). Eur J Heart Fail. 2017;19(11):1412–3.CrossRefPubMed
8.
Zurück zum Zitat Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:100.CrossRefPubMedPubMedCentral Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:100.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Sabaté E, editor. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. Sabaté E, editor. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
10.
Zurück zum Zitat Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.CrossRefPubMedPubMedCentral Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Hill MN, Miller NH, Degeest S, American Society of Hypertension Writing G, Materson BJ, Black HR, Izzo JL Jr, Oparil S, Weber MA. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens. 2011;5(1):56–63.CrossRefPubMed Hill MN, Miller NH, Degeest S, American Society of Hypertension Writing G, Materson BJ, Black HR, Izzo JL Jr, Oparil S, Weber MA. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens. 2011;5(1):56–63.CrossRefPubMed
12.
Zurück zum Zitat Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine. 2017;96(4): e5641.CrossRefPubMedPubMedCentral Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine. 2017;96(4): e5641.CrossRefPubMedPubMedCentral
14.
17.
Zurück zum Zitat Rodríguez-Chamorroa M, García-Jiménezb E, Amarilesc P, Rodríguez-Chamorrod A, Fause M. Revisión de tests de medición del cumplimiento terapéutico utilizados en la práctica clínica. Aten Prim. 2008;40(8):413–7.CrossRef Rodríguez-Chamorroa M, García-Jiménezb E, Amarilesc P, Rodríguez-Chamorrod A, Fause M. Revisión de tests de medición del cumplimiento terapéutico utilizados en la práctica clínica. Aten Prim. 2008;40(8):413–7.CrossRef
19.
Zurück zum Zitat Zack R, Okunade O, Olson E, Salt M, Amodeo C, Anchala R, Berwanger O, Campbell N, Chia YC, Damasceno A, Phuong Do TN, Tamdja Dzudie A, Fiuza M, Mirza F, Nitsch D, Ogedegbe G, Podpalov V, Schiffrin EL, Vaz Carneiro A, Lamptey P. Improving hypertension outcome measurement in low- and middle-income countries. Hypertension. 2019;73(5):990–7.CrossRefPubMed Zack R, Okunade O, Olson E, Salt M, Amodeo C, Anchala R, Berwanger O, Campbell N, Chia YC, Damasceno A, Phuong Do TN, Tamdja Dzudie A, Fiuza M, Mirza F, Nitsch D, Ogedegbe G, Podpalov V, Schiffrin EL, Vaz Carneiro A, Lamptey P. Improving hypertension outcome measurement in low- and middle-income countries. Hypertension. 2019;73(5):990–7.CrossRefPubMed
20.
Zurück zum Zitat Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, Aikens JE, Hunter CM, Velligan DI, Huntley K, Ogedegbe G, Rand CS, Schron E, Nilsen WJ. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5(4):470–82.CrossRefPubMedPubMedCentral Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, Aikens JE, Hunter CM, Velligan DI, Huntley K, Ogedegbe G, Rand CS, Schron E, Nilsen WJ. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5(4):470–82.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J, Group SR. Effect of intensive blood-pressure treatment on patient-reported outcomes. N Engl J Med. 2017;377(8):733–44.CrossRefPubMedPubMedCentral Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J, Group SR. Effect of intensive blood-pressure treatment on patient-reported outcomes. N Engl J Med. 2017;377(8):733–44.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, Berlowitz DR, Conroy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negron N, Powell J, Tamariz L, Whittle J, Wright JT Jr, Supiano MA, Cheung AK, Weintraub WS, Moran AE, Group SR. Cost-effectiveness of intensive versus standard blood-pressure control. N Engl J Med. 2017;377(8):745–55.CrossRefPubMedPubMedCentral Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, Berlowitz DR, Conroy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negron N, Powell J, Tamariz L, Whittle J, Wright JT Jr, Supiano MA, Cheung AK, Weintraub WS, Moran AE, Group SR. Cost-effectiveness of intensive versus standard blood-pressure control. N Engl J Med. 2017;377(8):745–55.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–54.CrossRef Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–54.CrossRef
24.
Zurück zum Zitat Nielsen JO, Shrestha AD, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects. J Hum Hypertens. 2017;31(1):14–21.CrossRefPubMed Nielsen JO, Shrestha AD, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects. J Hum Hypertens. 2017;31(1):14–21.CrossRefPubMed
25.
Zurück zum Zitat Mills KT, Rubinstein A, Irazola V, Chen J, Beratarrechea A, Poggio R, Dolan J, Augustovski F, Shi L, Krousel-Wood M, Bazzano LA, He J. Comprehensive approach for hypertension control in low-income populations: rationale and study design for the hypertension control program in Argentina. Am J Med Sci. 2014;348(2):139–45.CrossRefPubMedPubMedCentral Mills KT, Rubinstein A, Irazola V, Chen J, Beratarrechea A, Poggio R, Dolan J, Augustovski F, Shi L, Krousel-Wood M, Bazzano LA, He J. Comprehensive approach for hypertension control in low-income populations: rationale and study design for the hypertension control program in Argentina. Am J Med Sci. 2014;348(2):139–45.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat He J, Irazola V, Mills KT, Poggio R, Beratarrechea A, Dolan J, Chen CS, Gibbons L, Krousel-Wood M, Bazzano LA, Nejamis A, Gulayin P, Santero M, Augustovski F, Chen J, Rubinstein A, Investigators H. Effect of a community health worker-led multicomponent intervention on blood pressure control in low-income patients in Argentina: a randomized clinical trial. JAMA. 2017;318(11):1016–25.CrossRefPubMedPubMedCentral He J, Irazola V, Mills KT, Poggio R, Beratarrechea A, Dolan J, Chen CS, Gibbons L, Krousel-Wood M, Bazzano LA, Nejamis A, Gulayin P, Santero M, Augustovski F, Chen J, Rubinstein A, Investigators H. Effect of a community health worker-led multicomponent intervention on blood pressure control in low-income patients in Argentina: a randomized clinical trial. JAMA. 2017;318(11):1016–25.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697–716.CrossRefPubMed Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697–716.CrossRefPubMed
28.
Zurück zum Zitat Biffi A, Gallo G, Fernando F, Sirico F, Signorello MG, Messina M, Manole G, Triglione N, Volpe M. Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. J Hum Hypertens. 2022;36(3):308–14.CrossRefPubMed Biffi A, Gallo G, Fernando F, Sirico F, Signorello MG, Messina M, Manole G, Triglione N, Volpe M. Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. J Hum Hypertens. 2022;36(3):308–14.CrossRefPubMed
30.
Zurück zum Zitat de Oliveira-Filho AD, Morisky DE, Neves SJ, Costa FA, de Lyra Jr DP. The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults. Res Soc Adm Pharm. 2014;10(3):554–61.CrossRef de Oliveira-Filho AD, Morisky DE, Neves SJ, Costa FA, de Lyra Jr DP. The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults. Res Soc Adm Pharm. 2014;10(3):554–61.CrossRef
31.
Zurück zum Zitat Oliveira-Filho AD, Barreto-Filho JA, Neves SJ, Lyra Junior DP. Association between the 8-item Morisky Medication Adherence Scale (MMAS-8) and blood pressure control. Arq Bras Cardiol. 2012;99(1):649–58.CrossRefPubMed Oliveira-Filho AD, Barreto-Filho JA, Neves SJ, Lyra Junior DP. Association between the 8-item Morisky Medication Adherence Scale (MMAS-8) and blood pressure control. Arq Bras Cardiol. 2012;99(1):649–58.CrossRefPubMed
32.
Zurück zum Zitat Haley WE, Gilbert ON, Riley RF, Newman JC, Roumie CL, Whittle J, Kronish IM, Tamariz L, Wiggers A, Morisky DE, Conroy MB, Kovalik E, Kressin NR, Muntner P, Goff DC Jr, Group SSR. The association between Self-Reported Medication Adherence scores and systolic blood pressure control: a SPRINT baseline data study. J Am Soc Hypertens JASH. 2016;10(11):857-864 e852.CrossRefPubMed Haley WE, Gilbert ON, Riley RF, Newman JC, Roumie CL, Whittle J, Kronish IM, Tamariz L, Wiggers A, Morisky DE, Conroy MB, Kovalik E, Kressin NR, Muntner P, Goff DC Jr, Group SSR. The association between Self-Reported Medication Adherence scores and systolic blood pressure control: a SPRINT baseline data study. J Am Soc Hypertens JASH. 2016;10(11):857-864 e852.CrossRefPubMed
33.
Zurück zum Zitat DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794–811.CrossRefPubMed DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794–811.CrossRefPubMed
34.
Zurück zum Zitat Muntner P, Joyce C, Holt E, He J, Morisky D, Webber LS, Krousel-Wood M. Defining the minimal detectable change in scores on the eight-item Morisky Medication Adherence Scale. Ann Pharmacother. 2011;45(5):569–75.CrossRefPubMed Muntner P, Joyce C, Holt E, He J, Morisky D, Webber LS, Krousel-Wood M. Defining the minimal detectable change in scores on the eight-item Morisky Medication Adherence Scale. Ann Pharmacother. 2011;45(5):569–75.CrossRefPubMed
36.
Zurück zum Zitat Okello S, Nasasira B, Muiru AN, Muyingo A. Validity and reliability of a self-reported measure of antihypertensive medication adherence in Uganda. PLoS ONE. 2016;11(7): e0158499.CrossRefPubMedPubMedCentral Okello S, Nasasira B, Muiru AN, Muyingo A. Validity and reliability of a self-reported measure of antihypertensive medication adherence in Uganda. PLoS ONE. 2016;11(7): e0158499.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Valencia-Monsalvez F, Mendoza-Parra S, Luengo-Machuca L. Evaluación de la escala Morisky de adherencia a la medicación (MMAS-8) En adultos mayores de un centro de atencion primaria en Chile. Rev Peru Med Exp Salud Publica. 2017;34(2):245–9.CrossRefPubMed Valencia-Monsalvez F, Mendoza-Parra S, Luengo-Machuca L. Evaluación de la escala Morisky de adherencia a la medicación (MMAS-8) En adultos mayores de un centro de atencion primaria en Chile. Rev Peru Med Exp Salud Publica. 2017;34(2):245–9.CrossRefPubMed
38.
Zurück zum Zitat Korb-Savoldelli V, Gillaizeau F, Pouchot J, Lenain E, Postel-Vinay N, Plouin PF, Durieux P, Sabatier B. Validation of a French version of the 8-item Morisky medication adherence scale in hypertensive adults. J Clin Hypertens. 2012;14(7):429–34.CrossRef Korb-Savoldelli V, Gillaizeau F, Pouchot J, Lenain E, Postel-Vinay N, Plouin PF, Durieux P, Sabatier B. Validation of a French version of the 8-item Morisky medication adherence scale in hypertensive adults. J Clin Hypertens. 2012;14(7):429–34.CrossRef
39.
Zurück zum Zitat Ashur ST, Shamsuddin K, Shah SA, Bosseri S, Morisky DE. Reliability and known-group validity of the Arabic version of the 8-item Morisky Medication Adherence Scale among type 2 diabetes mellitus patients. Eastern Mediterr Health J. 2015;21(10):722–8.CrossRef Ashur ST, Shamsuddin K, Shah SA, Bosseri S, Morisky DE. Reliability and known-group validity of the Arabic version of the 8-item Morisky Medication Adherence Scale among type 2 diabetes mellitus patients. Eastern Mediterr Health J. 2015;21(10):722–8.CrossRef
40.
Zurück zum Zitat Al-Qazaz H, Hassali MA, Shafie AA, Sulaiman SA, Sundram S, Morisky DE. The eight-item Morisky Medication Adherence Scale MMAS: translation and validation of the Malaysian version. Diabetes Res Clin Pract. 2010;90(2):216–21.CrossRefPubMedPubMedCentral Al-Qazaz H, Hassali MA, Shafie AA, Sulaiman SA, Sundram S, Morisky DE. The eight-item Morisky Medication Adherence Scale MMAS: translation and validation of the Malaysian version. Diabetes Res Clin Pract. 2010;90(2):216–21.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Cook CL, Wade WE, Martin BC, Perri M 3rd. Concordance among three self-reported measures of medication adherence and pharmacy refill records. J Am Pharm Assoc JAPhA. 2005;45(2):151–9.CrossRef Cook CL, Wade WE, Martin BC, Perri M 3rd. Concordance among three self-reported measures of medication adherence and pharmacy refill records. J Am Pharm Assoc JAPhA. 2005;45(2):151–9.CrossRef
42.
Zurück zum Zitat Owolabi M, Olowoyo P, Miranda JJ, Akinyemi R, Feng W, Yaria J, Makanjuola T, Yaya S, Kaczorowski J, Thabane L, Van Olmen J, Mathur P, Chow C, Kengne A, Saulson R, Thrift AG, Joshi R, Bloomfield GS, Gebregziabher M, Parker G, Agyemang C, Modesti PA, Norris S, Ogunjimi L, Farombi T, Melikam ES, Uvere E, Salako B, Ovbiagele B, Initiative C. Gaps in hypertension guidelines in low- and middle-income versus high-income countries: a systematic review. Hypertension. 2016;68(6):1328–37.CrossRefPubMed Owolabi M, Olowoyo P, Miranda JJ, Akinyemi R, Feng W, Yaria J, Makanjuola T, Yaya S, Kaczorowski J, Thabane L, Van Olmen J, Mathur P, Chow C, Kengne A, Saulson R, Thrift AG, Joshi R, Bloomfield GS, Gebregziabher M, Parker G, Agyemang C, Modesti PA, Norris S, Ogunjimi L, Farombi T, Melikam ES, Uvere E, Salako B, Ovbiagele B, Initiative C. Gaps in hypertension guidelines in low- and middle-income versus high-income countries: a systematic review. Hypertension. 2016;68(6):1328–37.CrossRefPubMed
Metadaten
Titel
Blood Pressure Association with the 8-Item Morisky Medication Adherence Scale in Hypertensive Adults from Low-Resource Primary Care Settings: Results from a Prospective Cohort Nested within a Randomised Controlled Trial
verfasst von
Pablo Elías Gulayin
Andrea Beratarrechea
Rosana Poggio
Luz Gibbons
Analía Nejamis
Marilina Santero
Adolfo Rubinstein
Vilma Irazola
Publikationsdatum
18.05.2023
Verlag
Springer International Publishing
Erschienen in
High Blood Pressure & Cardiovascular Prevention / Ausgabe 3/2023
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI
https://doi.org/10.1007/s40292-023-00580-7

Weitere Artikel der Ausgabe 3/2023

High Blood Pressure & Cardiovascular Prevention 3/2023 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.